Sort
21,453 grants matching “tuberculosis”
Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker
$632,826Midori Kato-Maeda · University Of California, San Francisco · R01 · FY2025 · AI
Bioinformatics Core
$632,799Soumya Raychaudhuri · Brigham And Women'S Hospital · U19 · FY2019 · AI
M. tuberculosis exosome detection for pediatric TB diagnosis
$632,796Sylvia Lacourse · University Of Washington · R01 · FY2022 · AI
Improving Diagnostics and Neurocognitive Outcomes in HIV/AIDS-related Meningitis
$632,702David R Boulware · University Of Minnesota · R01 · FY2021 · NS
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases
$632,476Michael Berney · Albert Einstein College Of Medicine · R01 · FY2020 · AI
TUBERCULOSIS ELIMINATIONS AND LABORATORY GRANT APPLICATION
$632,410Lynn E Sosa · Connecticut State Dept Of Public Health · U52 · FY2014 · PS
Detecting pathogen and host factors on extracellular vesicles for pediatric TB diagnosis and management
$632,390Tony Y. Hu · Tulane University Of Louisiana · R01 · FY2023 · HD
Mycobacterial Genes, Antigens, and Vaccines
$632,374Harvard University (Sch Of Public Hlth) · R01 · FY2001 · AI
Targeting TB transmission hotspots to find undiagnosed TB in South Africa: a genomic, geospatial and modeling study (TARGET- TB)
$632,098Barun Mathema · Columbia University Health Sciences · R01 · FY2024 · AI
Administrative support, lab & data analytic services & leadership coordination
$632,086Paul Edward Farmer · Brigham And Women'S Hospital · U19 · FY2007 · AI
A Combination Intervention Package for Isoniazid Preventive Therapy in Ethiopia
$632,049Andrea Howard · Columbia University Health Sciences · R01 · FY2012 · AI
Evolutionary and Functional Significance of Novel Mutations in MDR-XDR TB
$632,047Faramarz Valafar · San Diego State University · R01 · FY2015 · AI
TB Aftermath
$631,996Jonathan E Golub · Johns Hopkins University · R01 · FY2021 · AI
A longitudinal cohort study to evaluate cardiovascular risk factors and disease in Haiti
$631,925Margaret Leighton McNairy · Weill Medical Coll Of Cornell Univ · R01 · FY2021 · HL
A longitudinal cohort study to evaluate cardiovascular risk factors and disease in Haiti
$631,925Margaret Leighton McNairy · Weill Medical Coll Of Cornell Univ · R01 · FY2020 · HL
Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU)
$631,871Mark Joseph Mulligan · New York University School Of Medicine · UM1 · FY2023 · AI
GENETIC FACTORS AND SUSCEPTIBILITY TO TUBERCULOSIS
$631,868Anne Goldfeld · Immune Disease Institute, Inc. · R01 · FY2006 · HL
Clinical And Therapeutic Studies Of Human Filariasis and Related Diseases
$631,464Thomas Nutman · National Institute Of Allergy And Infectious Diseases · ZIA · FY2012 · AI
Drugs targeting persistent Mycobacterium Tuberculosis
$631,455William Robert Jacobs · Albert Einstein College Of Medicine, Inc · R01 · FY2016 · AI
Understanding and Improving the Effectiveness of Public Health Laboratory Networks for Infectious Diseases in Ghana
$631,451Lee Frederick Schroeder · University Of Michigan At Ann Arbor · R01 · FY2023 · AI
Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases
$631,410Michael Berney · Albert Einstein College Of Medicine · R01 · FY2021 · AI
HIV, HCV and Liver Disease Among Injection Drug Users in Chennai, India
$631,218Shruti H Mehta · Johns Hopkins University · R01 · FY2010 · DA
Predicting neurodevelopmental risk in children born to mothers living with HIV in Kenya
$631,215Megan Song McHenry · Indiana University Indianapolis · R01 · FY2023 · HD
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis
$631,159Eric L Nuermberger · Johns Hopkins University · R61 · FY2022 · AI
MANAG. OF INFO RES ON THERAPEUTIC AGENTS FOR HIV
$631,148Cygnus Corporation · N01 · FY2000 · AI